Bracco Diagnostic Inc.
We are a multinational company active in the life science sector, a world leader in imaging diagnostics. Every day we seek and perfect increasingly advanced and sustainable techniques and solutions to open new paths in diagnostic imaging. So that the path of science and prevention does not stop, but continues to look ahead. Our Purpose is to improve people’s lives by shaping the future of prevention and precision imaging. Our Mission is to take pride in our commitment to patients, history of innovation, team talent, and sustainable approach.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)
About Us
- A successful track record in the development of clinically important products and related services to support clinical professionals to optimize diagnostic procedures.
- An innovative R&D player with efficient process oriented approach: R&D activities located in 3 integrated and specialized research centers in Italy, Switzerland and the United States and collaborations in place with major institutions and universities worldwide.
- Manufacturing activities located in Italy (Ceriano Laghetto, Torviscosa, and Colleretto Giacosa), Switzerland (Geneva), Japan (Saitama) and China (Shanghai).
- A continuous path to innovation, addressing unmet medical needs and improving production processes efficiency.
- A successful entrepreneurial tradition combined with solid managerial experience.
Mission Statement
We are a worldwide provider of diagnostic imaging solutions.
Our Company is committed to the discovery, development, manufacturing and marketing of imaging agents and solutions aimed at providing quality solutions in terms of diagnostic efficacy, patient safety and cost effectiveness.
The Bracco Group, established in 1927, is a multinational healthcare group, which operates in 90 countries worldwide.
Bracco extended the range of its offering over the years, thanks to acquisitions and strong innovation capabilities, entering the Magnetic Resonance imaging (MRI) market with ProHance® (gadoteridol) injection, 279.3 mg/mL and MultiHance® (gadobenate dimeglumine) injection, 529 mg/mL, consolidating its leadership in X-Ray/CT with Isovue® (iopamidol injection) and entering the Nuclear Medicine segment, with a leading position in fast growing niche areas of Positron Emission Tomography (PET), Cardiology, and Hepatobiliary Imaging. And it continues to devote considerable effort and substantial resources to create and develop innovative products and solutions addressing unmet or poorly met medical needs.
Since the Nineties, the Company has begun a globalization process. Bracco Imaging today operates in over 90 markets worldwide, either directly or indirectly through subsidiaries, joint ventures, license and distribution partnership agreements.
Moreover, Bracco Imaging's portfolio was broadened in 2008 with the acquisition of E-Z-EM, Inc., a major manufacturer of contrast media and medical devices for gastrointestinal (GI) radiology.
Other acquisitions between 2011 and 2012:
- (2011) BIPSO, a contrast agent production facility in Singen, Germany, near Konstanz.
- (2011) Swiss Medical Care, a Swiss company based in Lausanne active in research, production and marketing of automatic contrast agent delivery systems.
- (2012) Justesa Imagen Argentina, Brazil and Mexico, an important contrast agent distributor active throughout South America.
In 2016, ACIST Medical Systems has inaugurated its new European headquarters, combining the Maastricht offices and the Sittard assistance center and distribution facility into one large site that is spread over about 10,000 square meters in the Trilandis Business Park in Heerlen. ACIST Medical Systems is an American company based in Minnesota that was acquired by Bracco in 2001 and is now the world leader in solutions for the controlled administration of contrast agents in cardiology, with subsidiaries in Europe and Asia (among which Japan and China).
Over 1 million people annually undergo cardiovascular angiographic procedures using ACIST solutions and that number is set to grow.
In 2016 Bracco and Dompé announce that they have signed an agreement through which the Pharma Division of the Bracco Group will become part of the Italian Biopharmaceutical group led by Sergio Dompé. The agreement with Dompé is the climax of an all-Italian industrial project that promotes the values and traditions of two prestigious companies that have helped to write important pages in the history of Italian pharmaceuticals.
In 2019 Bracco Imaging Expands Portfolio of Personalized Diagnostics with the Acquisition of Blue Earth Diagnostics.
Bracco Imaging wants to consolidate its position as an open source provider of diagnostic imaging solutions aimed at providing quality solutions in terms of diagnostic efficacy, customer safety and cost effectiveness.